Zusammenfassung
Das Basalzellkarzinom, die aktinische Keratose als Carcinoma in situ und das Plattenepithelkarzinom gehören zu den nichtmelanozytären epithelialen Hauttumoren. Diese Hautkrebsformen zählen zu den häufigsten Krebsarten weltweit mit steigenden Inzidenzen. In den letzten Jahren ist das Wissen um die Pathogenese von nichtmelanozytärem Hautkrebs gestiegen, und durch die Kenntnis der pathologischen Signalkaskaden konnten neue therapeutische Möglichkeiten identifiziert werden, die bereits zur Entwicklung einer Reihe neuer Medikamente geführt haben. Mit diesem Review wird der aktuelle Erkenntnisstand zusammengefasst, wobei wir uns auf die wichtigsten Therapien beschränken.
Abstract
Basal cell carcinoma, actinic keratosis as a carcinoma in situ and squamous cell carcinoma are classified as non-melanoma epithelial skin cancers. These forms of skin cancer are thought to be the most common cancers worldwide with rising incidences. In the past years new insights into the pathogenesis of non-melanoma skin cancers have been gained. Through knowledge of the pathologic pathways, new treatment options have become available. This review summarizes the recent advantages of treatment options of non-melanoma skin cancer.
Literatur
Epidemiologisches Krebsregister Nordrhein Westfalen. http://www.krebsregister.nrw.de
Stang A (2007) Genital and nongenital nonmelanoma skin cancer: more epidemiological studies are needed. J Invest Dermatol 127(10):2296–2299
Crowson AN (2006) Basal cell carcinoma: biology, morphology and clinical implications. Modern pathology: an official journal of the United States and Canadian Academy of Pathology, Inc. [Research Support, Non-U.S. Gov’t Review] 19(Suppl 2):S127–S147
Nusslein-Volhard C, Wieschaus E (1980) Mutations affecting segment number and polarity in Drosophila. Nature 287(5785):795–801
Ingham PW, Placzek M (2006) Orchestrating ontogenesis: variations on a theme by sonic hedgehog. Nat Rev Genet 7(11):841–850
Cleaver JE (2005) Cancer in xeroderma pigmentosum and related disorders of DNA repair. Nat Rev Genet 5(7):564–573
Peris K, Micantonio T, Piccolo D, Fargnoli MC (2007) Dermoscopic features of actinic keratosis. JDDG 5(11):970–976
Oberyszyn TM (2008) Non-melanoma skin cancer: importance of gender, immunosuppressive status and vitamin D. Cancer Lett 261(2):127–136
Jensen AO, Svaerke C, Farkas D et al (2010) Skin cancer risk among solid organ recipients: a nationwide cohort study in Denmark. Acta Derm Venereol 90(5):474–479
Gerlini G, Romagnoli P, Pimpinelli N (2005) Skin cancer and immunosuppression. Crit Rev Oncol Hematol 56(1):127–136
Brantsch KD, Meisner C, Schonfisch B et al (2008) Analysis of risk factors determining prognosis of cutaneous squamous-cell carcinoma: a prospective study. Lancet Oncol 9(8):713–720
Goldberg LH, Mamelak AJ (2010) Review of actinic keratosis. Part I: etiology, epidemiology and clinical presentation. J Drugs Dermatol 9(9):1125–1132
Ulrich C, Jurgensen JS, Degen A et al (2009) Prevention of non-melanoma skin cancer in organ transplant patients by regular use of a sunscreen: a 24 months, prospective, case-control study. Br J Dermatol 161(Suppl 3):78–84
Moloney F, Vestergaard M, Radojkovic B, Damian D (2010) Randomized, double-blinded, placebo controlled study to assess the effect of topical 1% nicotinamide on actinic keratoses. Br J Dermatol 162(5):1138–1139
Reuschenbach M, Tran T, Faulstich F et al (2011) High-risk human papillomavirus in non-melanoma skin lesions from renal allograft recipients and immunocompetent patients. Br J Cancer 104(8):1334–1341
Marquez C, Bair SM, Smithberger E et al (2010) Systemic retinoids for chemoprevention of non-melanoma skin cancer in high-risk patients. J Drugs Dermatol 9(7):753–758
Pugliano-Mauro M, Goldman G (2010) Mohs surgery is effective for high-risk cutaneous squamous cell carcinoma. Dermatol Surg 36(10):1544–1553
Gibson SJ, Imbertson LM, Wagner TL et al (1995) Cellular requirements for cytokine production in response to the immunomodulators imiquimod and S-27609. J Interferon Cytokine Res 15(6):537–545
Lien MH, Sondak VK (2011) Nonsurgical treatment options for Basal cell carcinoma. J Skin Cancer 2011:571734
Geisse J, Caro I, Lindholm J et al (2004) Imiquimod 5% cream for the treatment of superficial basal cell carcinoma: results from two phase III, randomized, vehicle-controlled studies. J Am Acad Dermatol 50(5):722–733
Gollnick H, Barona CG, Frank RG et al (2008) Recurrence rate of superficial basal cell carcinoma following treatment with imiquimod 5% cream: conclusion of a 5-year long-term follow-up study in Europe. Eur J Dermatol 18(6):677–682
Quist SR, Gollnick HP (2011) Imiquimod 3.75% cream (Zyclara) for the treatment of actinic keratoses. Exp Opin Pharmacother 12(3):451–461
Daniell MD, Hill JS (1991) A history of photodynamic therapy. Aust N Z J Surg 61(5):340–348
Morton CA, Whitehurst C, McColl JH et al (2001) Photodynamic therapy for large or multiple patches of Bowen disease and basal cell carcinoma. Arch Dermatol 137(3):319–324
Serra-Guillen C, Nagore E, Hueso L et al (2011) A randomized comparative study of tolerance and satisfaction in the treatment of actinic keratosis of the face and scalp between 5% imiquimod cream and photodynamic therapy with methyl aminolaevulinate. Br J Dermatol 164(2):429–433
Schlaak M, Simon JC (2010) Topical treatment of actinic keratoses with low-dose 5-fluorouracil in combination with salicylic acid – pilot study. JDDG 8(3):174–178
Siller G, Rosen R, Freeman M et al (2010) PEP005 (ingenol mebutate) gel for the topical treatment of superficial basal cell carcinoma: results of a randomized phase IIa trial. Aust J Dermatol 51(2):99–105
Von Hoff DD, LoRusso PM, Rudin CM et al (2009) Inhibition of the hedgehog pathway in advanced basal-cell carcinoma. N Engl J Med 361(12):1164–1172
Rudin CM, Hann CL, Laterra J et al (2009) Treatment of medulloblastoma with hedgehog pathway inhibitor GDC-0449. N Engl J Med 361(12):1173–1178
Lorusso PM, Rudin CM, Reddy JC et al (2011) Phase I trial of hedgehog pathway inhibitor GDC-0449 in patients with refractory, locally-advanced or metastatic solid tumors. Clin Cancer Res 17(8):2512–2520
Oro AE, Higgins KM, Hu Z et al (1997) Basal cell carcinomas in mice overexpressing sonic hedgehog. Science 276(5313):817–821
Elmets CA, Viner JL, Pentland AP et al (2010) Chemoprevention of nonmelanoma skin cancer with celecoxib: a randomized, double-blind, placebo-controlled trial. J Natl Cancer Inst 102(24):1835–1844
Bito T, Sumita N, Ashida M et al (2011) Inhibition of epidermal growth factor receptor and PI3 K/Akt signaling suppresses cell proliferation and survival through regulation of stat3 activation in human cutaneous squamous cell carcinoma. J Skin Cancer 2011:874571
Ridd K, Bastian BC (2010) Somatic mutation of epidermal growth factor receptor in a small subset of cutaneous squamous cell carcinoma. J Invest Dermatol 130(3):901–903
Fogarty GB, Conus NM, Chu J, McArthur G (2007) Characterization of the expression and activation of the epidermal growth factor receptor in squamous cell carcinoma of the skin. Br J Dermatol 156(1):92–98
Toll A, Salgado R, Yebenes M et al (2010) Epidermal growth factor receptor gene numerical aberrations are frequent events in actinic keratoses and invasive cutaneous squamous cell carcinomas. Exp Dermatol 19(2):151–153
Schlauder SM, Calder KB, Moody P, Morgan MB (2007) HER2 and EGFR expression in cutaneous spindle squamous cell carcinoma. Am J Dermatopathol 29(6):559–563
Cranmer LD, Engelhardt C, Morgan SS (2010) Treatment of unresectable and metastatic cutaneous squamous cell carcinoma. Oncologist 15(12):1320–1328
Maubec E, Duvillard P, Laouenan C et al (2010) Cetuximab as first-line monotherapy in patients with skin unresectable squamous cell carcinoma: final results of a phase II multicenter study. J Clin Oncol ASCO Annual Meeting Proceedings (Post-Meeting Edition) 28(15_suppl, May 20 Supplement):8510
Bauman JE, Eaton KD, Martins RG (2007) Treatment of recurrent squamous cell carcinoma of the skin with cetuximab. Arch Dermatol 143(7):889–892
Suen JK, Bressler L, Shord SS et al (2007) Cutaneous squamous cell carcinoma responding serially to single-agent cetuximab. Anti Cancer Drugs 18(7):827–829
Jalili A, Pinc A, Pieczkowski F et al (2008) Combination of an EGFR blocker and a COX-2 inhibitor for the treatment of advanced cutaneous squamous cell carcinoma. JDDG 6(12):1066–1069
Weinberg RA (2006) The biology of cancer. Garland Science
Interessenkonflikt
Der korrespondierende Autor gibt an, dass kein Interessenkonflikt besteht.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Schlaak, M., von Bartenwerffer, W. & Mauch, C. Medikamentöse Therapie nichtmelanozytärer epithelialer Tumore. Hautarzt 62, 430–435 (2011). https://doi.org/10.1007/s00105-010-2044-2
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00105-010-2044-2